Views: 3197
Faster, more reliable health care, full stop.
On-demand health assessments every minute, ensuring: (1) the right patient receives (2) the right drug, (3) at the right time point.
Unchecked Hemodynamic Compromise and Inflammation
Inflammasense is transforming the way health care and clinical trials are conducted by integrating advanced modular medical monitoring (ECG, PPG, Temperature, Body Motion), neural Autonomic Neurography (ANG) monitoring and blood metabolite protein analyses to provide real-time, objective biomarkers for disease progression and treatment selection; treatment efficacy is modeled for each individual patient.
This continuous dual-method approach enhances precision, reliability, and scalability in clinical health care and clinical research; it is critical for hemodynamic compromise and inflammatory disease, wherein intermittent traditional assessments fail.
Clinical monitoring of medical conditions typically rely on intermittent coarse vital signs; they are intermittent at best and can be inconsistent and prone to bias. By incorporating real time (measured every millisecond) vital sign measurements (ECG, PPG, Temp, Body motion) and ANG (Autonomic Neurography) monitoring, InflammaSense provides objective, physiological insights into how each patient may respond to specific treatment. This real-time multi-modal data allows clinicians to:
Detect subtle improvements or worsening disease progression,
Identify early physiological indicators of treatment response,
Improve patient selection methods to identify those most likely to benefit from specific treatments.
Patients with hemodynamic decompensation in shock, inflammatory disorders such as Sepsis may need specific medications and or neuromodulation treatments dependent on their neuro-immune system configuration:
Our wearable tech helps the military detect and assess hemodynamic decompensation associated with hemorrhage due to kinetic based penetrating wounds, while our continuous vital sign and ANG monitoring over 1 weeks time/per charge allows us to monitor for inflammatory diseases such as sepsis. This enables faster intervention. Our development of closed loop systems will enhance resilience in active-duty personnel and veterans.
By combining neural and molecular data, Inflammasense enhances clinical trial design, execution, and analysis, leading to:
By combining neural and molecular data, Inflammasense enhances precision guided patient treatments leading to:
More accurate therapy use in critically ill patients improving likelihood of survival
More accurate therapy use in patients faced with multiple mental health medication, therapy, or neuromodulation options
$13.6B Sepsis Based Hospital Losses per year.
Projected revenue: $ 8M year 1 in 20 hospitals, 30M-$60M+ in clinical trials, $20-40M+ in defense, $30M+ in corporate wellness.
First-to-market solution with patented AI-driven biomarker technology
Proprietary Dataset access allowing for refined predictive model generation
Validated by BARDA, NIH, and DARPA funding with FDA clearance submission in process and pipeline established
Multiple world-wide patents filed
We’re making clinical trials more efficient by offering precise patient stratification, reducing costs, and increasing the likelihood of successful outcomes. With our cutting-edge Point of Care (PoC) biomarker technology, we’re paving the way for faster, more reliable trials that ultimately lead to breakthrough treatments.
InflammaSense harnesses the power of Autonomic Neurography or millisecond based vital sign measured coupled to “ANG” and Molecular Point of Care (PoC) biomarkers to predict disease severity early and accurately. Our 10 min recordings predict likelihood of individual disease response to therapeutics, radically enhancing accurate treatment selection.
